{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:17:40Z","timestamp":1787167060032,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s12020-019-02128-z","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T11:22:48Z","timestamp":1573212168000},"page":"457-465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Teriparatide (rhPTH 1\u201334) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5862-8958","authenticated-orcid":false,"given":"Gerdi","family":"Tuli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Buganza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Tessaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Einaudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Matarazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"de Sanctis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"2128_CR1","doi-asserted-by":"publisher","first-page":"17055","DOI":"10.1038\/nrdp.2017.55","volume":"3","author":"M Mannstadt","year":"2017","unstructured":"M. Mannstadt, J.P. Bilezikian, R.V. Thakker, F.M. Hannan, B.L. Clarke, L. Rejnmark, D.M. Mitchell, T.J. Vokes, K.K. Winer, D.M. Shoback, Hypoparathyroidism. Nat. Rev. Dis. Prim. 3, 17055 (2017). \nhttps:\/\/doi.org\/10.1038\/nrdp.2017.55","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"6","key":"2128_CR2","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/jc.2015-3907","volume":"101","author":"ML Brandi","year":"2016","unstructured":"M.L. Brandi, J.P. Bilezikian, D. Shoback, R. Bouillon, B.L. Clarke, R.V. Thakker, A.A. Khan, J.T. Potts Jr., Management of hypoparathyroidism: summary statement and guidelines. J. Clin. Endocrinol. Metab. 101(6), 2273\u20132283 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"2128_CR3","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-15-0628","volume":"173","author":"J Bollerslev","year":"2015","unstructured":"J. Bollerslev, L. Rejnmark, C. Marcocci, D.M. Shoback, A. Sitges-Serra, W. van Biesen, O.M. Dekkers; European Society of Endocrinology, European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. Eur. J. Endocrinol. 173(2), G1\u201320 (2015)","journal-title":"Eur. J. Endocrinol."},{"issue":"12","key":"2128_CR4","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1002\/jbmr.1800","volume":"27","author":"C Cipriani","year":"2012","unstructured":"C. Cipriani, D. Irani, J.P. Bilezikian, Safety of osteoanabolic therapy: a decade of experience. J. Bone Miner. Res. 27(12), 2419\u20132428 (2012)","journal-title":"J. Bone Miner. Res."},{"issue":"10117","key":"2128_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"D.L. Kendler, F. Marin, C.A.F. Zerbini, L.A. Russo, S.L. Greenspan, V. Zikan, A. Bagur, J. Malouf-Sierra, P. Lakatos, A. Fahrleitner-Pammer, E. Lespessailles, S. Minisola, J.J. Body, P. Geusens, R. M\u00f6ricke, P. Lop\u00e8z-Romero, Effects of teriparatide and risedronate on new fractures in post menopausal women with severe osteroporosis (VERO): a multicenter, double-blind, double-dummy, randomized controlled trial. Lancet. 391(10117), 230\u2013240 (2018)","journal-title":"Lancet."},{"issue":"4","key":"2128_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00223-018-0437-x","volume":"103","author":"N Napoli","year":"2018","unstructured":"N. Napoli, B.L. Langdahl, \u00d6. Ljunggren, E. Lespessailles, G. Kapetanos, T. Kocjan, T. Nikolic, P. Eiken, H. Petto, T. Moll, E. Lindh, F. Marin, Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo\u00ae Observational Study (ExFOS). Calcif. Tissue Int. 103(4), 359\u2013371 (2018)","journal-title":"Calcif. Tissue Int."},{"key":"2128_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bone.2018.07.013","volume":"116","author":"BL Langdahl","year":"2018","unstructured":"B.L. Langdahl, S. Silverman, S. Fujiwara, K. Saag, N. Napoli, S. Soen, H. Enomoto, T.E. Melby, D.P. Disch, F. Marin, J.H. Krege, Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone. 116, 58\u201366 (2018)","journal-title":"Bone."},{"issue":"2","key":"2128_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00223-018-0485-2","volume":"104","author":"S Silverman","year":"2019","unstructured":"S. Silverman, B.L. Langdahl, S. Fujiwara, K. Saag, N. Napoli, S. Soen, H. Enomoto, T.E. Melby, D.P. Disch, F. Marin, J.H. Krege, Reduction of hip and other fractures in patients receiving teriparatide in real-world clinical practice: integrated analysis of four prospective observational studies. Calcif. Tissue Int. 104(2), 193\u2013200 (2019)","journal-title":"Calcif. Tissue Int"},{"key":"2128_CR9","unstructured":"Food and Drug Administration (FDA). Drug Approval Package- Netpara. (2015). \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125511Orig1s000TOC.cfm"},{"key":"2128_CR10","unstructured":"European Medicine Agency (EMA). Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 February 2017. (2017). \nhttps:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2017"},{"issue":"10","key":"2128_CR11","first-page":"3480","volume":"83","author":"KK Winer","year":"1998","unstructured":"K.K. Winer, J.A. Yanovski, B. Sarani, G.B. Cutler Jr., A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J. Clin. Endocrinol. Metab. 83(10), 3480\u20133486 (1998)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"2128_CR12","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1210\/jc.2002-021736","volume":"88","author":"KK Winer","year":"2003","unstructured":"K.K. Winer, C.W. Ko, J.C. Reynolds, K. Dowdy, M. Keil, D. Peterson, L.H. Gerber, C. McGarvey, G.B. Cutler Jr., Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J. Clin. Endocrinol. Metab. 88(9), 4214\u20134220 (2003)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"2128_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1210\/jc.2011-1908","volume":"97","author":"KK Winer","year":"2012","unstructured":"K.K. Winer, B. Zhang, J.A. Shrader, D. Peterson, M. Smith, P.S. Albert, G.B. Cutler Jr., Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J. Clin. Endocrinol. Metab. 97(2), 391\u2013399 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"2128_CR14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","volume":"276","author":"KK Winer","year":"1996","unstructured":"K.K. Winer, J.A. Yanovski, G.B. Cutler Jr., Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 276(8), 631\u2013636 (1996)","journal-title":"JAMA"},{"issue":"11","key":"2128_CR15","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.2555","volume":"30","author":"RI Gafni","year":"2015","unstructured":"R.I. Gafni, L.C. Guthrie, M.H. Kelly, B.A. Brillante, C.M. Christie, J.C. Reynolds, N.A. Yovetich, R. James, M.T. Collins, Transient increased calcium and calcitriol requirements after discontinuation of human synthetic parathyroid hormone 1-34 (hPTH 1-34) replacement therapy in hypoparathyroidism. J. Bone Miner. Res. 30(11), 2112\u20132118 (2015)","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"2128_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1055\/s-0032-1308971","volume":"44","author":"G D\u00edaz-Soto","year":"2012","unstructured":"G. D\u00edaz-Soto, M. Mora-Porta, J. Nicolau, V. Perea, I. Halperin, M. Puig-Domingo, Efficacy and safety of long term treatment of unresponsive hypoparathyroidism using multipulse subcutaneous infusion of teriparatide. Horm. Metab. Res. 44(9), 708\u2013710 (2012)","journal-title":"Horm. Metab. Res."},{"issue":"6","key":"2128_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1507\/endocrj.K06-053","volume":"53","author":"M Shiohara","year":"2006","unstructured":"M. Shiohara, R. Shiozawa, K. Kurata, H. Matsuura, F. Arai, T. Yasuda, K. Koike, Effect of parathyroid hormone administration in a patient with severe hypoparathyroidism caused by gain-of-function mutation of calcium-sensing receptor. Endocr. J. 53(6), 797\u2013802 (2006)","journal-title":"Endocr. J."},{"issue":"3","key":"2128_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","volume":"165","author":"KK Winer","year":"2014","unstructured":"K.K. Winer, K.A. Fulton, P.S. Albert, G.B. Cutler Jr., Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J. Pediatr. 165(3), 556\u2013563.e1 (2014)","journal-title":"J. Pediatr."},{"issue":"6","key":"2128_CR19","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1210\/jc.2009-2464","volume":"95","author":"KK Winer","year":"2010","unstructured":"K.K. Winer, N. Sinaii, J. Reynolds, D. Peterson, K. Dowdy, G.B. Cutler Jr., Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J. Clin. Endocrinol. Metab. 95(6), 2680\u20132688 (2010)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"2128_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000479867","volume":"89","author":"V Saraff","year":"2016","unstructured":"V. Saraff, A. Rothenbuhler, W. H\u00f6gler, A. Linglart, Continuous subcutaneous recombinant parathyroid hormone (1-34) infusion in the management of childhood hypoparathyroidism associated with malabsorption. Horm. Res. Paediatr. 89(4), 271\u2013277 (2016)","journal-title":"Horm. Res. Paediatr."},{"key":"2128_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jpeds.2018.08.010","volume":"203","author":"KK Winer","year":"2018","unstructured":"K.K. Winer, A. Kelly, A. Johns, B. Zhang, K. Dowdy, L. Kim, J.C. Reynolds, P.S. Albert, G.B. Cutler Jr., Long-term parathyroid hormone 1-34 replacement therapy in children with hypoparathyroidism. J. Pediatr. 203, 391\u2013399.e1 (2018)","journal-title":"J. Pediatr."},{"issue":"1\u20132","key":"2128_CR22","first-page":"53","volume":"27","author":"P Matarazzo","year":"2014","unstructured":"P. Matarazzo, G. Tuli, L. Fiore, A. Mussa, F. Feyles, V. Peiretti, R. Lala et al. Teriparatide (rhPTH) treatment in children with syndromic hypoparathyroidism. J. Pediatr. Endocrinol. Metab. 27(1\u20132), 53\u201359 (2014)","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"9","key":"2128_CR23","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1210\/jc.2007-2552","volume":"93","author":"KK Winer","year":"2008","unstructured":"K.K. Winer, N. Sinaii, D. Peterson, B. Sainz Jr, G.B. Cutler Jr., Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J. Clin. Endocrinol. Metab. 93(9), 3389\u20133395 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"2128_CR24","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1210\/jc.2011-1359","volume":"96","author":"A Linglart","year":"2011","unstructured":"A. Linglart, A. Rothenbuhler, I. Gueorgieva, P. Lucchini, C. Silve, P. Bougn\u00e8res, Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism. J. Clin. Endocrinol. Metab. 96(11), 3308\u20133312 (2011)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"2128_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1515\/JPEM.2008.21.4.385","volume":"21","author":"S Sanda","year":"2008","unstructured":"S. Sanda, K.P. Schlingmann, R.S. Newfield, Autosomal dominant hypoparathyroidism with severe hypomagnesemia and hypocalcemia, successfully treated with recombinant PTH and continuous subcutaneous magnesium infusion. J. Pediatr. Endocrinol. Metab. 21(4), 385\u2013391 (2008)","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"3","key":"2128_CR26","first-page":"141","volume":"138","author":"W St\u00f6gmann","year":"1990","unstructured":"W. St\u00f6gmann, E. Bohrn, W. Woloszczuk, Initial experiences with substitution treatment of hypoparathyroidism with synthetic human parathyroid hormone. Monatsschr. Kinderheilkd. 138(3), 141\u2013146 (1990)","journal-title":"Monatsschr. Kinderheilkd."},{"issue":"16","key":"2128_CR27","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMc063043","volume":"356","author":"RS Newfield","year":"2007","unstructured":"R.S. Newfield, Recombinant PTH for initial management of neonatal hypocalcemia. N. Engl. J. Med. 356(16), 1687\u20131688 (2007)","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"2128_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jpeds.2011.09.022","volume":"160","author":"YH Cho","year":"2012","unstructured":"Y.H. Cho, M. Tchan, B. Roy, R. Halliday, M. Wilson, S. Dutt, S. Siew, C. Munns, N. Howard, Recombinant parathyroid hormone therapy for severe neonatal hypoparathyroidism. J. Pediatr. 160(2), 345\u2013348 (2012)","journal-title":"J. Pediatr."},{"issue":"11","key":"2128_CR29","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1080\/14712598.2016.1238455","volume":"16","author":"G Marcucci","year":"2016","unstructured":"G. Marcucci, G. Della Pepa, M.L. Brandi, Natpara for the treatment of hypoparathyroidism. Expert. Opin. Biol. Ther. 16(11), 1417\u20131424 (2016)","journal-title":"Expert. Opin. Biol. Ther."},{"key":"2128_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000491047","volume":"51","author":"G Marcucci","year":"2019","unstructured":"G. Marcucci, M.L.A. Brandi, New era for chronic management of hypoparathyroidism: parathyroid hormone peptides. Front. Horm. Res. 51, 165\u2013171 (2019). \nhttps:\/\/doi.org\/10.1159\/000491047","journal-title":"Front. Horm. Res."},{"issue":"4","key":"2128_CR31","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/01926230490462138","volume":"32","author":"JL Vahle","year":"2004","unstructured":"J.L. Vahle, G.G. Long, G. Sandusky, M. Westmore, Y.L. Ma, M. Sato, Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol. Pathol. 32(4), 426\u2013438 (2004)","journal-title":"Toxicol. Pathol."},{"issue":"9","key":"2128_CR32","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1210\/en.2002-220149","volume":"143","author":"M Sato","year":"2002","unstructured":"M. Sato, J. Vahle, A. Schmidt, M. Westmore, S. Smith, E. Rowley, L.Y. Ma, Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology. 143(9), 3230\u20133242 (2002)","journal-title":"Endocrinology."},{"issue":"3","key":"2128_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"J.L. Vahle, M. Sato, G.G. Long, J.K. Young, P.C. Francis, J.A. Engelhardt, M.S. Westmore, Y. Linda, J.B. Nold, Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol. 30(3), 312\u2013321 (2002)","journal-title":"Toxicol. Pathol."},{"issue":"7","key":"2128_CR34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/01926230601072301","volume":"34","author":"J Jolette","year":"2006","unstructured":"J. Jolette, C.E. Wilker, S.Y. Smith, N. Doyle, J.F. Hardisty, A.J. Metcalfe, T.B. Marriott, J. Fox, D.S. Wells, Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol. Pathol. 34(7), 929\u2013940 (2006)","journal-title":"Toxicol. Pathol."},{"issue":"7","key":"2128_CR35","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1359\/jbmr.2002.17.7.1151","volume":"17","author":"AH Tashjian Jr.","year":"2002","unstructured":"A.H. Tashjian Jr., B.A. Chabner, Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J. Bone Miner. Res. 17(7), 1151\u20131161 (2002)","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"2128_CR36","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1359\/jbmr.080807","volume":"23","author":"JL Vahle","year":"2008","unstructured":"J.L. Vahle, U. Zuehlke, A. Schmidt, M. Westmore, P. Chen, M. Sato, Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J. Bone Miner. Res. 23(12), 2033\u20132039 (2008)","journal-title":"J. Bone Miner. Res."},{"issue":"17","key":"2128_CR37","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJM199910213411701","volume":"341","author":"SJ Silverberg","year":"1999","unstructured":"S.J. Silverberg, E. Shane, T.P. Jacobs, E. Siris, J.P. Bilezikian, A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N. Engl. J. Med. 341(17), 1249\u20131255 (1999)","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"2128_CR38","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1002\/jbmr.1768","volume":"27","author":"EB Andrews","year":"2012","unstructured":"E.B. Andrews, A.W. Gilsenan, K. Midkiff, B. Sherrill, Y. Wu, B.H. Mann, D. Masica, The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J. Bone Miner. Res. 27(12), 2429\u20132437 (2012)","journal-title":"J. Bone Miner. Res."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02128-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-019-02128-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02128-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T19:49:39Z","timestamp":1604692179000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-019-02128-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2128"],"URL":"https:\/\/doi.org\/10.1007\/s12020-019-02128-z","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"assertion":[{"value":"16 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all parents of the individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}